- Home
- Publications
- Publication Search
- Publication Details
Title
From natural product to marketed drug: the tiacumicin odyssey
Authors
Keywords
-
Journal
NATURAL PRODUCT REPORTS
Volume 30, Issue 1, Pages 161-174
Publisher
Royal Society of Chemistry (RSC)
Online
2012-10-31
DOI
10.1039/c2np20080e
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety Analysis of Fidaxomicin in Comparison With Oral Vancomycin for Clostridium difficile Infections
- (2012) K. Weiss et al. CLINICAL INFECTIOUS DISEASES
- Fidaxomicin Inhibits Spore Production in Clostridium difficile
- (2012) Farah Babakhani et al. CLINICAL INFECTIOUS DISEASES
- Fidaxomicin Is an Inhibitor of the Initiation of Bacterial RNA Synthesis
- (2012) Irina Artsimovitch et al. CLINICAL INFECTIOUS DISEASES
- Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials
- (2012) Derrick W. Crook et al. CLINICAL INFECTIOUS DISEASES
- Current Status of Clostridium difficile Infection Epidemiology
- (2012) F. C. Lessa et al. CLINICAL INFECTIOUS DISEASES
- Fidaxomicin: The Newest Addition to the Armamentarium Against Clostridium difficile Infections
- (2012) Jason W. Lancaster et al. CLINICAL THERAPEUTICS
- Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence
- (2012) Konstantinos Z. Vardakas et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial
- (2012) Oliver A Cornely et al. LANCET INFECTIOUS DISEASES
- Postantibiotic Effect of Fidaxomicin and Its Major Metabolite, OP-1118, against Clostridium difficile
- (2011) Farah Babakhani et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Characterization of a Sugar-O-methyltransferase TiaS5 Affords New Tiacumicin Analogues with Improved Antibacterial Properties and Reveals Substrate Promiscuity
- (2011) Siwen Niu et al. CHEMBIOCHEM
- Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent Infections
- (2011) Kathleen M. Mullane et al. CLINICAL INFECTIOUS DISEASES
- Clostridium difficileInfection: A Comprehensive Review
- (2011) Melina Kachrimanidou et al. CRITICAL REVIEWS IN MICROBIOLOGY
- New target for inhibition of bacterial RNA polymerase: ‘switch region’
- (2011) Aashish Srivastava et al. CURRENT OPINION IN MICROBIOLOGY
- Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile
- (2011) F. Babakhani et al. JOURNAL OF MEDICAL MICROBIOLOGY
- Fidaxomicin versus Vancomycin forClostridium difficileInfection
- (2011) Thomas J. Louie et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fidaxomicin: A Macrocyclic Antibiotic for the Treatment ofClostridium difficileInfection
- (2011) Jennifer S Hardesty et al. PHARMACOTHERAPY
- The role of toxin A and toxin B in the virulence of Clostridium difficile
- (2011) Glen P. Carter et al. TRENDS IN MICROBIOLOGY
- In Vitro Activity of Fidaxomicin (OPT-80) Tested against Contemporary Clinical Isolates of Staphylococcus spp. and Enterococcus spp.
- (2010) D. J. Biedenbach et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effects of Inoculum, pH, and Cations on the In Vitro Activity of Fidaxomicin (OPT-80, PAR-101) against Clostridium difficile
- (2010) F. Babakhani et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The transcription inhibitor lipiarmycin blocks DNA fitting into the RNA polymerase catalytic site
- (2010) Audrey Tupin et al. EMBO JOURNAL
- Economic healthcare costs of Clostridium difficile infection: a systematic review
- (2010) S.S. Ghantoji et al. JOURNAL OF HOSPITAL INFECTION
- Current approaches to exploit actinomycetes as a source of novel natural products
- (2010) Olga Genilloud et al. JOURNAL OF INDUSTRIAL MICROBIOLOGY & BIOTECHNOLOGY
- Natural Products Version 2.0: Connecting Genes to Molecules
- (2010) Christopher T. Walsh et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Characterization of Tiacumicin B Biosynthetic Gene Cluster Affording Diversified Tiacumicin Analogues and Revealing a Tailoring Dihalogenase
- (2010) Yi Xiao et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin
- (2010) G. W. Tannock et al. MICROBIOLOGY-SGM
- A sea of biosynthesis: marine natural products meet the molecular age
- (2010) Amy L. Lane et al. NATURAL PRODUCT REPORTS
- Marine Streptomyces as a novel source of bioactive substances
- (2010) Selvakumar Dharmaraj WORLD JOURNAL OF MICROBIOLOGY & BIOTECHNOLOGY
- Molecular insights on the biosynthesis of antitumour compounds by actinomycetes
- (2010) Carlos Olano et al. Microbial Biotechnology
- Bioactive compounds from marine actinomycetes
- (2009) Renu Solanki et al. INDIAN JOURNAL OF MICROBIOLOGY
- Frequency and characterisation of spontaneous lipiarmycin-resistant Enterococcus faecalis mutants selected in vitro
- (2009) Maxime Gualtieri et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- In Vitro Activity of OPT-80 Tested against Clinical Isolates of Toxin-Producing Clostridium difficile
- (2008) J. A. Karlowsky et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Safety, Tolerance, and Pharmacokinetic Studies of OPT-80 in Healthy Volunteers following Single and Multiple Oral Doses
- (2008) Y. K. Shue et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical Outcomes, Safety, and Pharmacokinetics of OPT-80 in a Phase 2 Trial with Patients with Clostridium difficile Infection
- (2008) T. Louie et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- OPT-80 Eliminates Clostridium difficile and Is Sparing of Bacteroides Species during Treatment of C. difficile Infection
- (2008) T. J. Louie et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Both Oral Metronidazole and Oral Vancomycin Promote Persistent Overgrowth of Vancomycin-Resistant Enterococci during Treatment of Clostridium difficile-Associated Disease
- (2008) W. N. Al-Nassir et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The Case for Vancomycin as the Preferred Drug for Treatment ofClostridium difficileInfection
- (2008) John G. Bartlett CLINICAL INFECTIOUS DISEASES
- Historical Perspectives on Studies ofClostridium difficileandC. difficileInfection
- (2008) John G. Bartlett CLINICAL INFECTIOUS DISEASES
- Renaissance in antibacterial discovery from actinomycetes
- (2008) R BALTZ CURRENT OPINION IN PHARMACOLOGY
- OPT-80, a macrocyclic antimicrobial agent for the treatment ofClostridium difficileinfections: a review
- (2008) Michael Gerber et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis
- (2008) M. Kurabachew et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started